Clinical Trials Logo

Clinical Trial Summary

A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy


Clinical Trial Description

This study is an open Label, non-randomized, single-arm and multi-centered phase II clinical trial. It plans to evaluate the safety and efficacy of fruquintinib in advanced pancreatic cancer patients who failed second-line gemcitabine or 5-FU based chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05257122
Study type Interventional
Source Fudan University
Contact Jieyun Zhang
Phone +8618801735823
Email Dr_JYZ@outlook.com
Status Not yet recruiting
Phase Phase 2
Start date February 2022
Completion date February 2024

See also
  Status Clinical Trial Phase
Completed NCT01454180 - Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets Phase 2
Active, not recruiting NCT05304936 - HCW9218 for Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05620732 - Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T N/A
Recruiting NCT05053971 - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Recruiting NCT05143151 - CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer Phase 1/Phase 2
Withdrawn NCT05238831 - SMMART Adaptive Clinical Treatment (ACT) Trial Early Phase 1
Recruiting NCT05759923 - First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours Phase 1
Recruiting NCT05526443 - Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Completed NCT03033225 - Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study Phase 2
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2
Recruiting NCT04550494 - Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Phase 2